BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Campbell JS, Johnson MM, Bauer RL, Hudkins KL, Gilbertson DG, Riehle KJ, Yeh MM, Alpers CE, Fausto N. Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis. Differentiation. 2007;75:843-852. [PMID: 17999742 DOI: 10.1111/j.1432-0436.2007.00235.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Gowda R, Jones NR, Banerjee S, Robertson GP. Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy. J Nanomed Nanotechnol 2013;4:184. [PMID: 25013742 DOI: 10.4172/2157-7439.1000184] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
2 Alves A, Mamede A, Alves M, Oliveira P, Rocha S, Botelho M, Maia C. Glycolysis Inhibition as a Strategy for Hepatocellular Carcinoma Treatment? CCDT 2018;19:26-40. [DOI: 10.2174/1568009618666180430144441] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
3 Oseini AM, Roberts LR. PDGFRalpha: a new therapeutic target in the treatment of hepatocellular carcinoma? Expert Opin Ther Targets 2009;13:443-54. [PMID: 19335066 DOI: 10.1517/14728220902719233] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.7] [Reference Citation Analysis]
4 Rombouts K, Carloni V. The fibrotic microenvironment as a heterogeneity facet of hepatocellular carcinoma. Fibrogenesis Tissue Repair 2013;6:17. [PMID: 24350713 DOI: 10.1186/1755-1536-6-17] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
5 Riehle KJ, Johnson MM, Johansson F, Bauer RL, Hayes BJ, Gilbertson DG, Haran AC, Fausto N, Campbell JS. Tissue-type plasminogen activator is not necessary for platelet-derived growth factor-c activation. Biochim Biophys Acta 2014;1842:318-25. [PMID: 24269585 DOI: 10.1016/j.bbadis.2013.11.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
6 Lee JI, Wright JH, Johnson MM, Bauer RL, Sorg K, Yuen S, Hayes BJ, Nguyen L, Riehle KJ, Campbell JS. Role of Smad3 in platelet-derived growth factor-C-induced liver fibrosis. Am J Physiol Cell Physiol 2016;310:C436-45. [PMID: 26632601 DOI: 10.1152/ajpcell.00423.2014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
7 Moawad AW, Szklaruk J, Lall C, Blair KJ, Kaseb AO, Kamath A, Rohren SA, Elsayes KM. Angiogenesis in Hepatocellular Carcinoma; Pathophysiology, Targeted Therapy, and Role of Imaging. J Hepatocell Carcinoma 2020;7:77-89. [PMID: 32426302 DOI: 10.2147/JHC.S224471] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
8 Guzman G, Chennuri R, Voros A, Boumendjel R, Locante A, Patel R, Valyi-nagy T. Nucleometric Study of Anisonucleosis, Diabetes and Oxidative Damage in Liver Biopsies of Orthotopic Liver Transplant Recipients with Chronic Hepatitis C Virus Infection. Pathol Oncol Res 2011;17:191-9. [DOI: 10.1007/s12253-010-9296-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
9 Boor P, Bábíčková J, Steegh F, Hautvast P, Martin IV, Djudjaj S, Nakagawa T, Ehling J, Gremse F, Bücher E, Eriksson U, van Roeyen CR, Eitner F, Lammers T, Floege J, Peutz-kootstra CJ, Ostendorf T. Role of Platelet-Derived Growth Factor-CC in Capillary Rarefaction in Renal Fibrosis. The American Journal of Pathology 2015;185:2132-42. [DOI: 10.1016/j.ajpath.2015.04.022] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
10 Lahsnig C, Mikula M, Petz M, Zulehner G, Schneller D, van Zijl F, Huber H, Csiszar A, Beug H, Mikulits W. ILEI requires oncogenic Ras for the epithelial to mesenchymal transition of hepatocytes and liver carcinoma progression. Oncogene 2009;28:638-50. [PMID: 19015638 DOI: 10.1038/onc.2008.418] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 4.8] [Reference Citation Analysis]
11 di Tomaso E, London N, Fuja D, Logie J, Tyrrell JA, Kamoun W, Munn LL, Jain RK. PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment. PLoS One 2009;4:e5123. [PMID: 19352490 DOI: 10.1371/journal.pone.0005123] [Cited by in Crossref: 83] [Cited by in F6Publishing: 81] [Article Influence: 6.9] [Reference Citation Analysis]
12 Lai Q, Vitale A, Manzia TM, Foschi FG, Levi Sandri GB, Gambato M, Melandro F, Russo FP, Miele L, Viganò L, Burra P, Giannini EG; Associazione Italiana per lo Studio del Fegato (AISF) HCC Special Interest Group. Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics. Cancers (Basel) 2019;11:E1568. [PMID: 31618961 DOI: 10.3390/cancers11101568] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
13 Ding XX, Zhu QG, Zhang SM, Guan L, Li T, Zhang L, Wang SY, Ren WL, Chen XM, Zhao J, Lin S, Liu ZZ, Bai YX, He B, Zhang HQ. Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy. Oncotarget. 2017;8:55715-55730. [PMID: 28903454 DOI: 10.18632/oncotarget.18382] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 10.3] [Reference Citation Analysis]
14 Lim BJ, Lee WK, Lee HW, Lee KS, Kim JK, Chang HY, Lee JI. Selective deletion of hepatocyte platelet-derived growth factor receptor α and development of liver fibrosis in mice. Cell Commun Signal 2018;16:93. [PMID: 30509307 DOI: 10.1186/s12964-018-0306-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
15 Heindryckx F, Gerwins P. Targeting the tumor stroma in hepatocellular carcinoma. World J Hepatol 2015; 7(2): 165-176 [PMID: 25729472 DOI: 10.4254/wjh.v7.i2.165] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
16 Petrelli A. Polypharmacological Kinase Inhibitors: New Hopes for Cancer Therapy. In: Peters J, editor. Polypharmacology in Drug Discovery. Hoboken: John Wiley & Sons, Inc.; 2012. pp. 149-65. [DOI: 10.1002/9781118098141.ch8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
17 Wright JH, Johnson MM, Shimizu-Albergine M, Bauer RL, Hayes BJ, Surapisitchat J, Hudkins KL, Riehle KJ, Johnson SC, Yeh MM, Bammler TK, Beyer RP, Gilbertson DG, Alpers CE, Fausto N, Campbell JS. Paracrine activation of hepatic stellate cells in platelet-derived growth factor C transgenic mice: evidence for stromal induction of hepatocellular carcinoma. Int J Cancer. 2014;134:778-788. [PMID: 23929039 DOI: 10.1002/ijc.28421] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
18 Petrelli A, Valabrega G. Multitarget drugs: the present and the future of cancer therapy. Expert Opin Pharmacother 2009;10:589-600. [PMID: 19284362 DOI: 10.1517/14656560902781907] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 4.0] [Reference Citation Analysis]
19 Lee C, Zhang F, Tang Z, Liu Y, Li X. PDGF-C: a new performer in the neurovascular interplay. Trends Mol Med 2013;19:474-86. [PMID: 23714575 DOI: 10.1016/j.molmed.2013.04.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
20 Hayes BJ, Riehle KJ, Shimizu-Albergine M, Bauer RL, Hudkins KL, Johansson F, Yeh MM, Mahoney WM Jr, Yeung RS, Campbell JS. Activation of platelet-derived growth factor receptor alpha contributes to liver fibrosis. PLoS One 2014;9:e92925. [PMID: 24667490 DOI: 10.1371/journal.pone.0092925] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
21 Kikuchi A, Monga SP. PDGFRα in liver pathophysiology: emerging roles in development, regeneration, fibrosis, and cancer. Gene Expr 2015;16:109-27. [PMID: 25700367 DOI: 10.3727/105221615X14181438356210] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
22 Siegel A. Moving targets in hepatocellular carcinoma: hepatic progenitor cells as novel targets for tyrosine kinase inhibitors. Gastroenterology 2008;135:733-5. [PMID: 18692053 DOI: 10.1053/j.gastro.2008.07.036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
23 Anderberg C, Li H, Fredriksson L, Andrae J, Betsholtz C, Li X, Eriksson U, Pietras K. Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts. Cancer Res. 2009;69:369-378. [PMID: 19118022 DOI: 10.1158/0008-5472.can-08-2724] [Cited by in Crossref: 152] [Cited by in F6Publishing: 88] [Article Influence: 12.7] [Reference Citation Analysis]
24 van Zijl F, Mair M, Csiszar A, Schneller D, Zulehner G, Huber H, Eferl R, Beug H, Dolznig H, Mikulits W. Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge. Oncogene. 2009;28:4022-4033. [PMID: 19718050 DOI: 10.1038/onc.2009.253] [Cited by in Crossref: 124] [Cited by in F6Publishing: 119] [Article Influence: 10.3] [Reference Citation Analysis]
25 Zheng L, Zhao C, Du Y, Lin X, Jiang Y, Lee C, Tian G, Mi J, Li X, Chen Q, Ye Z, Huang L, Wang S, Ren X, Xing L, Chen W, Huang D, Gao Z, Zhang S, Lu W, Tang Z, Wang B, Ju R, Li X. PDGF-CC underlies resistance to VEGF-A inhibition and combinatorial targeting of both suppresses pathological angiogenesis more efficiently. Oncotarget 2016;7:77902-15. [PMID: 27788490 DOI: 10.18632/oncotarget.12843] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
26 Wei T, Zhang LN, Lv Y, Ma XY, Zhi L, Liu C, Ma F, Zhang XF. Overexpression of platelet-derived growth factor receptor alpha promotes tumor progression and indicates poor prognosis in hepatocellular carcinoma. Oncotarget. 2014;5:10307-10317. [PMID: 25333264 DOI: 10.18632/oncotarget.2537] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 5.8] [Reference Citation Analysis]
27 Li X, Kumar A, Zhang F, Lee C, Li Y, Tang Z, Arjuna P. VEGF-independent angiogenic pathways induced by PDGF-C. Oncotarget 2010;1:309-14. [PMID: 20871734 DOI: 10.18632/oncotarget.141] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 3.9] [Reference Citation Analysis]
28 Raica M, Cimpean AM. Platelet-Derived Growth Factor (PDGF)/PDGF Receptors (PDGFR) Axis as Target for Antitumor and Antiangiogenic Therapy. Pharmaceuticals (Basel) 2010;3:572-99. [PMID: 27713269 DOI: 10.3390/ph3030572] [Cited by in Crossref: 103] [Cited by in F6Publishing: 91] [Article Influence: 9.4] [Reference Citation Analysis]
29 Zender L, Villanueva A, Tovar V, Sia D, Chiang DY, Llovet JM. Cancer gene discovery in hepatocellular carcinoma. J Hepatol. 2010;52:921-929. [PMID: 20385424 DOI: 10.1016/j.jhep.2009.12.034] [Cited by in Crossref: 120] [Cited by in F6Publishing: 113] [Article Influence: 10.9] [Reference Citation Analysis]
30 Egners A, Rezaei M, Kuzmanov A, Poitz DM, Streichert D, Müller-Reichert T, Wielockx B, Breier G. PHD3 Acts as Tumor Suppressor in Mouse Osteosarcoma and Influences Tumor Vascularization via PDGF-C Signaling. Cancers (Basel) 2018;10:E496. [PMID: 30563292 DOI: 10.3390/cancers10120496] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
31 Awuah PK, Nejak-Bowen KN, Monga SP. Role and regulation of PDGFRα signaling in liver development and regeneration. Am J Pathol 2013;182:1648-58. [PMID: 23529017 DOI: 10.1016/j.ajpath.2013.01.047] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]